Brain Circuitry Therapeutics for Schizophrenia

Inclusion Criteria: * Inclusion criteria * Capable of giving informed consent as evaluated by the treating psychiatrist * Informed Consent signed by the subject * Patients aged 18 - 65 years diagnosed with a schizophrenia spectrum disorder (including schizophrenia, schizoaffective or non-organic psychosis, psychotic disorder NOS) according to DSM-5 criteria * Clinically stable condition judged by their treating psychiatrist * Background antipsychotic medication treatments have remained unchanged for at least 4 weeks * No hospitalization in acute psychiatry ward at least 3 months prior to study entry Specific exclusion criteria related to psychopathology * Comorbid and clinically active current major depressive episode determined by the treating psychiatrist. * Active psychotic symptoms. In particular, patients that at Baseline have a PANSS scores of more than 4 in any of the following PANSS items: delusions, suspiciousness/persecution and hallucinatory behaviour will be considered not stable enough to participate. * Significant extrapyramidal side-effects quantified by total score of mSAS \> 12. * Increased sedation due to use of medication (slowing, drowsiness, slurred speech etc.) * Active daily use of substances (i.e. cocaine), including for therapeutically medical purposes (e.g., methadone substitution) Exclusion criteria related to MRI or TMS * History of fainting spells of unknown or undetermined aetiology that might constitute seizures * History of multiple seizures or diagnosis of epilepsy * Any progressive (e.g., neurodegenerative) neurological disorder such as multiple sclerosis or Parkinson's disease * Chronic uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * Metallic objects/implants (excluding dental fillings) unless cleared to be MRI compatible (i.e. MRI compatible joint replacement) * Any implants controlled by physiological signs in/near the head * Pacemaker * Implanted medication pump * Vagal nerve stimulator * Deep brain stimulator or TENS unit * Ventriculo-peritoneal shunt * Cochlear implant * Impaired ability to sense heat/pain, open wounds etc. * Increased intracranial pressure * Intracranial lesion, from a known genetic disorder or from acquired neurologic disease (e.g. stroke, tumor, cerebral palsy, severe head injury, or significant dysmorphology). * History of head injury resulting in prolonged loss of consciousness (\>15minutes) or neurological sequelae * Ongoing pregnancy and breastfeeding. All participants capable of becoming pregnant will be required to have active contraception; any participant who is pregnant or breastfeeding will not be enrolled in the study. Other exclusion criteria * Clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cancer, pulmonary decompensation etc.) * Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, intellectual retardation, dementia, etc. of the subject * Having legal obligation for psychiatric treatment. * Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation. * Previous enrolment into the current investigation * Enrolment of the PI, his/her family members, employees and other dependent persons.